Previously unreported adverse drug reactions can be dif ficult to detect and it may be even more difficult to estab Topical beta-blockers have become very popular in the treatment of glaucoma since the first, timolol, was intro duced in 1978. All topical beta-blockers were thought to have a similar side effect profile, with rare serious systemic effects such as bronchospasm, and few ocular adverse effects. These ocular effects could be divided into the subjective (burning and stinging on instillation, eye pain, foreign body sensation) and the objective (external eye inflammation, punctate keratopathy, dry eye syn drome and corneal anaesthesia).
Topical beta-blockers have become very popular in the treatment of glaucoma since the first, timolol, was intro duced in 1978. All topical beta-blockers were thought to have a similar side effect profile, with rare serious systemic effects such as bronchospasm, and few ocular adverse effects. These ocular effects could be divided into the subjective (burning and stinging on instillation, eye pain, foreign body sensation) and the objective (external eye inflammation, punctate keratopathy, dry eye syn drome and corneal anaesthesia). 1 Intraocular inflam mation had not previously been described as an adverse effect of these drugs.
Metipranolol (Glauline, Smith and Nephew) is a topical Eye (1992) 6, 277-279 beta-blocker licensed in the United Kingdom for the treat ment of glaucoma in 1986, although it was in widespread use in Europe for many years before that and was recently marketed in the United States (1991). Some authors sug gested that metipranolol was less well tolerated than other beta-blockers with a high incidence of subjective but not objective side effects.2•3 In February 1990, we saw 5 cases of either granulomatous anterior uveitis or blepharocon junctivitis or both in patients using metipranolol. These associations were reported by "yellow card" to the Com mittee on Safety of Medicines (CSM) who had one pre vious report of iritis with this drug and to the Pharmaceutical Company who had no previous reports either from Germany or the United Kingdom where more than 700,000 prescriptions had been issued up to 1990 (Smith & Nephew, personal communication).
We suspected that metipranolol was responsible for these inflammatory reactions and undertook a review of all of our patients on this drug. The details have been pub lished elsewhere. 4 Since this association has not been pre viously described, we felt that it was important to establish a cause and effect relationship. We therefore identified further patients who had developed ocular inflammation whilst receiving metipranolol and with their consent rechallenged with this drug.
RECHALLENGE STUDY
The protocol for this study was submitted to the District Ethics Committee and approval obtained.
After full explanation patients gave written consent for the following study: double blind comparison between metipranolol 0.3% and timolol 0.5%. It was felt to be unethical to use placebo in glaucoma patients and there fore timolol was used as the comparable drug. All patients had pre-trial lOPs controlled by other ophthalmic topical beta-blockers.
Patients were given two identical bottles, labelled right eye and left eye, one containing metipranolol 0.3% and the other timolol maleate 0.5% eye drops in a randomised fashion. Patients were told to apply two drops from the appropriate bottle twice a day. Patients were given enough drug for two weeks, at which time they returned to the clinic for review.
Patients were to be reviewed every two weeks but had access to the investigators at all times. The study was intended to last a maximum of six months but was to be terminated at any time if the patient wished or if signs of ocular inflammation or elevation in lOP developed.
Before entering the study all the patients underwent: (1) full medical history and ocular examination including the measurement of visual acuity, lOP and grading of the following parameters (using scores from 0-3), watering, blurring, photophobia, conjunctival injection, corneal oedema, keratic precipitates (KPs), aqueous flare, aqueous cells, anterior vitreous cells, hypopion and posterior synechia.
(2) chest X-ray. (3) full blood count, erythrocyte sedimentation rate, urea and electrolytes, VORL, toxoplasma and toxocara serol ogy, serum angiotensin converting enzyme and fasting blood sugar.
RESULTS
Thirteen patients agreed to participate in the rechallenge but only 7 (2 males, 5 females, mean age 71.5 years) com pleted the study. The reasons for the withdrawal of 6 patients are given in Table I .
The previous adverse effects suffered by the 7 patients were bilateral granulomatous anterior uveitis in 4 patients; unilateral granulomatous anterior uveitis in 2 patients and periorbital dermatitis in 1 patient. Of the 2 patients with unilateral granulomatous anterior uveitis, 1 was receiving metipranolol in both eyes and the other in the affected eye only.
Screening of these patients showed that 1 had positive toxoplasma serology, and another had non-insulin dependent diabetes mellitus. In neither case was it thought that these contributed to the inflammation or the elevation in lOP.
All of the patients developed an objective documented adverse reaction in the eye which was treated with meti pranolol 0.3% within 2-14 days and the trial was termi nated in each case. Three eyes of 3 patients had granulomatous anterior uveitis, 2 eyes of 2 patients had blepharoconjunctivitis, 1 eye of 1 patient had periorbital dermatitis, and 1 eye of the seventh patient which was white and quiet on examination had a rise in lOP from 25 mmHg pre-trial to 42 mmHg (Table 11) . One of the patients (No 3) who developed metipranolol-induced granuloma tous anterior uveitis had co-existing blepharoconjunctiv itis with secondary ectropion due to the skin changes and loss of lOP control (610P 22 mmHg). None of the eyes T. AKINGBEHIN ET AL.
which received timolol showed any adverse reactions during the period of the study, 5 of these eyes had pre-trial metipranolol-induced adverse events.
The 2 eyes with blepharoconjunctivitis and 2 of the 3 eyes with granulomatous anterior uveitis were treated immediately with topical steroids and they all showed complete resolution of symptoms and signs within two weeks. The third eye with granulomatous anterior uveitis, 1 eye with periorbital dermatitis and 1 eye with loss of intraocular pressure control did not receive any active treatment following the termination of the trial drug. These 3 eyes also showed complete resolution of symp toms and signs within two weeks. All the 7 eyes with meti pranolol associated adverse reactions were later treated with another anti-glaucoma medication (timolol in 6 eyes and levobunolol in 1 eye) and have shown no adverse reac tion to the alternative topical beta-blocker to date.
DISCUSSION
Definitive proof of cause and effect relationship in adverse drug reactions can be difficult to obtain. Naranjo et ae laid down certain criteria which ideally should be fulfilled to prove causality, although this is not always possible.
These criteria are-(1) The event should be described frequently and hence be well documented. (6) The patients should suffer a similar effect with similar drugs.
(7) The event should recur on challenge with the suspected drug.
The most powerful of these criteria is whether the adverse effect recurs on challenge with the suspected drug. The results of this rechallenge study provides unequivocal evidence that metipranolol causes periorbital dermatitis, blepharoconjunctivitis, granulomatous anterior uveitis and elevation in lOP. What is not immediately apparent in this study is whether all these adverse reac tions are various stages of a specific metipranolol-induced syndrome. Unfortunately the study was unable to address this question because the investigators were bound by the ethics of the trial to terminate the rechallenge once there was an objective evidence of adverse reaction. However, from previous review of all patients receiving metiprano-101 by the authors, there is evidence to suggest that the various types of reaction can occur in isolation for months without progression. These reactions have also been found in combination. This lack of specificity in the type of response to metipranolol is pathologically quite interesting. It has been suggested that a possible explanation for these adverse reactions, which appear to have been reported mainly in the United Kingdom, is the sterilisation of the multidose metipranolol bottles by gamma radiation from January 1989. There is no scientific evidence to sup port this view and we have identified patients in the United Kingdom with metipranolol associated adverse reactions who received multidose metipranolol bottles sterilised by ethylene oxide pre-1989. Also in Europe, where the bottles of metipranolol are not sterilised by radiation, there were at least 9 spontaneous adverse reaction reports of anterior uveitis (Germany 5, France, Holland and Swit zerland 4) by early 1991 before the publication of our report,4 (Smith and Nephew -personal communication).
One of the main privileges which the law bestows on registered medical practitioners is the right to prescribe and we owe it to our patients to remain vigilant with regard to adverse drug reactions and communicate all unwanted and unexpected events to the CSM using the "yellow card" scheme. It is only by reporting all suspected events to a central agency that evidence can be gathered quickly and effective action taken to alert clinicians of post -marketing adverse reactions. "Vigilance is important but so is seren dipity" (Prescriber's Journal 1991, vol 31, no 1 -Editorial).
